Horizon Pharma PLC | Mutual Funds
Mutual Funds that own Horizon Pharma PLC
Vanguard Small Cap Index Fund
4,153,481
2.49%
55,475
0.09%
07/31/2018
Vanguard Total Stock Market Index Fund
4,125,425
2.48%
4,646
0.01%
07/31/2018
iShares Russell 2000 ETF
3,492,752
2.1%
-1,866
0.15%
09/06/2018
Glenmede Small Cap Equity Fund
2,899,445
1.74%
-15,731
1.54%
04/30/2018
DFA US Small Cap Portfolio
2,373,295
1.42%
-68,859
0.23%
04/30/2018
Vanguard Small Cap Growth Index Fund
2,372,943
1.42%
36,713
0.19%
07/31/2018
William Blair Small Mid Cap Growth Fund
2,268,765
1.36%
202,015
1.78%
06/30/2018
Vanguard Extended Market Index Fund
2,181,956
1.31%
17,567
0.06%
07/31/2018
Government Pension Fund - Global (The)
2,158,674
1.3%
213,892
0.01%
12/31/2017
Rhenman & Partners Fund - Healthcare Equity L/S
1,954,912
1.17%
-467,178
2.93%
12/31/2017
| Address |
Connaught House
Dublin Dublin 4
Ireland
|
|
Employees
|
- |
| Website |
http://www.horizontherapeutics.com |
| Updated |
07/08/2019 |
| Horizon Pharma Plc engages in the research, development and market of pharmaceutical products. The medicines intend to treat arthritis, inflammation and orphan diseases. It distributes its products under the brands such as Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos and Vimovo. |
